British researchers have used T2* measures of cardiac iron loading to show the value of a new drug treatment for b-thalassemia, a genetic blood disorder. The laborious clinical trial involved transporting a mobile MRI system three times from London to the Mediterranean island of Sardinia.
British researchers have used T2* measures of cardiac iron loading to show the value of a new drug treatment for b-thalassemia, a genetic blood disorder. The laborious clinical trial involved transporting a mobile MRI system three times from London to the Mediterranean island of Sardinia.
Researchers found a 40% increase in T2* values, which represents a statistically significant drop in myocardial iron among beta-thalassemia patients who received a combined deferoxamine/deferiprone treatment for 12 months, according to Dr. Mark A. Tanner, a contrast MR researcher at Royal Brompton Hospital in London. T2* increases in the placebo-treated group were much smaller.
The results suggest that combined deferoxamine/deferiprone therapy will reduce the likelihood of cardiac iron loading and the threat of lethal complications, Tanner said.
"I suggest that combined therapy be considered in all patients who fail to achieve adequate iron load status on deferoxamine alone," he said.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.